Mineralys Therapeutics, Inc.

Now that AstraZeneca’s oral PCSK9 inhibitor AZD0780 has successfully navigated a Phase IIb trial, attention can now shift to baxdrostat, a second cardiovascular candidate the UK firm believes can have

Cargo Therapeutics’ decision to end all development for its allogeneic cell therapy technology platform and its cancer cell therapy candidates is not the kind of news the biopharmaceutical sector need

Mineralys reported data from a pair of clinical trials for lorundrostat (MLS-101) in uncontrolled or resistant hypertension on 10 March that it asserts could provide a new treatment option for about 1

“We’re at an exciting juncture in medicine where the perceived scientific boundaries in treatment across therapeutic areas continue to dissolve.” These words from Jeffrey Jones , chief medical office